1. Anaplastic Thyroid Carcinoma, Version 2.2015.
- Author
-
Haddad, Robert I, Lydiatt, William M, Ball, Douglas W, Busaidy, Naifa Lamki, Byrd, David, Callender, Glenda, Dickson, Paxton, Duh, Quan-Yang, Ehya, Hormoz, Haymart, Megan, Hoh, Carl, Hunt, Jason P, Iagaru, Andrei, Kandeel, Fouad, Kopp, Peter, Lamonica, Dominick M, McCaffrey, Judith C, Moley, Jeffrey F, Parks, Lee, Raeburn, Christopher D, Ridge, John A, Ringel, Matthew D, Scheri, Randall P, Shah, Jatin P, Smallridge, Robert C, Sturgeon, Cord, Wang, Thomas N, Wirth, Lori J, Hoffmann, Karin G, and Hughes, Miranda
- Subjects
Rare Diseases ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Antineoplastic Combined Chemotherapy Protocols ,Carboplatin ,Docetaxel ,Doxorubicin ,Humans ,Paclitaxel ,Radiotherapy ,Intensity-Modulated ,Taxoids ,Thyroid Carcinoma ,Anaplastic ,Thyroid Neoplasms ,Thyroidectomy ,Oncology & Carcinogenesis - Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
- Published
- 2015